Bayer Healthcare Shares Latest Analyses of Vitrakvi for Patients with TRK Fusion Cancer

On September 16, 2021, Bayer Healthcare released data from three subset analyses and one matching-adjusted indirect comparison model for Vitrakvi® (larotrectinib). These reports showcase the product's clinical profile and add to its safety data for patients with solid tumors harboring an NTRK gene fusion, which is also known as TRK fusion cancer.

Key elements of Bayer's news includes:

• An updated analyses on three Vitrakvi clinical trials of adult patients with non-central nervous system (CNS) TRK fusion cancer, which showed an overall response rate of 67% and a median duration of response of 49.3 months.
• A sub-analysis published on the investigator-assessed overall response rate and duration of patients' responses that were stratified.
• Data on the incidence of fractures from three Phase I and II clinical trials of patients with solid and CNS tumors treated with Vitrakvi monotherapy was also published.
• Electronic poster of a matching-adjusted indirect comparison that evaluated the efficacy and safety observed in clinical trials with Vitrakvi.

"These analyses add to the body of evidence for the compound, which has the largest dataset and longest follow-up of any TRK inhibitor," says Bayer.

Read more at Bayer Healthcare's website.

Posted 9/21/2021